Medicine & Life Sciences
Agar
5%
Asymptomatic Infections
25%
AZD0914
12%
Azithromycin
38%
Bacterial Vaginosis
14%
Ceftriaxone
29%
Chlamydia trachomatis
13%
Chlorhexidine
6%
Complex Mixtures
6%
Cross-Over Studies
5%
Dapivirine
10%
Doxycycline
7%
Ebola Hemorrhagic Fever
7%
Ebolavirus
7%
Equipment and Supplies
6%
Ethiopia
27%
Female Genitalia
9%
Gardnerella vaginalis
8%
Gonorrhea
49%
Guinea
17%
Infections
7%
Klebsiella pneumoniae
12%
Latex
6%
Medroxyprogesterone Acetate
5%
Microbial Drug Resistance
11%
microbisporicin
12%
Mycoplasma genitalium
7%
Neisseria gonorrhoeae
100%
Neopterin
7%
No-Observed-Adverse-Effect Level
6%
non-ribosomal peptide synthase
9%
Phase III Clinical Trials
7%
Phosphopyruvate Hydratase
6%
Polyketide Synthases
8%
Polymerase Chain Reaction
9%
Reverse Transcriptase Inhibitors
6%
Routine Diagnostic Tests
9%
Serum
5%
Sexual and Gender Minorities
24%
Urine
5%
Urine Specimen Collection
7%
Vagina
6%
Validation Studies
6%
Viruses
6%
Visceral Leishmaniasis
35%
Western Africa
7%
Chemistry
Antimicrobial Agent
21%
Azithromycin
27%
Ceftriaxone
18%
Ciprofloxacin
26%
Erythromycin
7%
Food
9%
Minimum Inhibitory Concentration
14%
Mining
6%
Mutation
7%
Polyketide
6%
Resistance
21%
Strain
14%
Toilet
9%